

Establishment Labs Announces the Appointment of Dr. David Hung to Its Board of Directors

Establishment Labs, a global breast implant and medical technology company, is pleased to announce the appointment of Dr. David Hung to the company's Board of Directors.

New York, NY ([PRWEB](http://www.prweb.com)) February 09, 2016 -- Establishment Labs, a global breast implant and medical technology company, is pleased to announce the appointment of Dr. David Hung to the company's Board of Directors.

"We are honored to welcome David to our Board of Directors. He is a world class scientist and an exceptional entrepreneur," said Juan Jose Chacon Quiros, CEO of Establishment Labs. "David's knowledge and experience will be invaluable to our company as we expand into new markets and develop innovative products that improve patient outcomes."

Dr. David Hung is the Founder, President, and CEO of Medivation, a San Francisco-based life sciences company. Dr. Hung first identified and in-licensed enzalutamide, a novel androgen receptor antagonist, in 2005, and led the development of enzalutamide from discovery and preclinical testing to approval for human use as Xtandi. Today, Xtandi is approved for the treatment of metastatic castration resistant prostate cancer in more than 55 countries, with worldwide net sales exceeding \$2 billion on an annualized basis.

"Establishment Labs is taking a rigorous approach to innovation in an industry where it is much needed," said David Hung. "Establishment has already created a product portfolio that I believe will set new standards in the industry, and they are well-positioned to deliver next generation products that will further address unmet medical needs and improve patient outcomes."

Ed Schutter, Director at Establishment Labs and CEO of Arbor Pharmaceuticals, commented, "We welcome David to the Board of Directors and greatly respect his accomplishments at Medivation developing Xtandi. The talent and knowledge at Establishment Labs is remarkable for this industry, and the cross disciplinary approach will lead to better and safer options across breast reconstruction and aesthetics."

Prior to Medivation, Dr. Hung was President and CEO of Pro-Duct Health, a venture capital-backed company focused on the early detection of breast cancer. Dr. Hung was the inventor of the Pro-Duct catheter which enabled the detection of early cellular atypia in women at high risk for breast cancer and he led the development of the catheter which resulted in its FDA clearance. Three years after raising a total of \$22M in venture funding, the company sold for \$168M in 2001 to Cytoc Corporation, one of the world's largest makers of cervical pap smears. Prior to Pro-Duct Health, Dr. Hung was Vice President of Lead Discovery and Development at Chiron Corporation. Dr. Hung received an M.D. Alpha Omega Alpha from the University of California, San Francisco, and an A.B. summa cum laude from Harvard University.

About Establishment Labs:

Establishment Labs is a global, privately held, breast implant and medical technology company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants (<http://www.motivaimplants.com>). Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional

Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC.

**Contact Information**

Luis Manuel Gutiérrez

Establishment Labs

<http://motivaimplants.com/>

+1 (646) 595-6626

Online Web 2.0 Version

You can read the online version of this press release [here](#).